Cargando…
Contemporary use of Selexipag in pulmonary arterial hypertension associated with congenital heart disease: a case series
BACKGROUND: There are significant risks of parenteral prostacyclin use in patients with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD), which may limit their use. Selexipag is an oral, selective prostacyclin analogue that has been shown to reduce disease progressi...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7793171/ https://www.ncbi.nlm.nih.gov/pubmed/33442633 http://dx.doi.org/10.1093/ehjcr/ytaa320 |